|
|
 Previous Article | Table of Contents | Next Article 
Long-term engraftment of fresh human myeloma cells in SCID mice
FJ Feo-Zuppardi, CW Taylor, K Iwato, MH Lopez, TM Grogan, A Odeleye, EM Hersh and SE Salmon
Department of Internal Medicine, Arizona Cancer Center, College of
Medicine, University of Arizona, Tucson 85724.
Using highly purified myeloma cells from patient bone marrow, we
established human-murine myeloma chimeras in severe combined
immunodeficiency (SCID) mice and documented secretion of monoclonal human
immunoglobulins (Hulgs) in the mice for up to 299 days. Monoclonality of
circulating Hulgs was found only when highly purified myeloma cells were
injected intraperitoneally. In contrast, injection of unfractionated
myeloma marrow led to the development of polyclonal Hulgs in the SCID mice.
The criteria for myeloma engraftment included prolonged presence of
monoclonal Hulgs in the sera of SCID mice and/or detection of human myeloma
cells in their tissues by immunohistochemical examination. Ninety-one
percent (10/11) of the fresh purified myeloma specimens engrafted in the
SCID mice. Fifty-five percent (6/11) of the patient samples resulted in
human B-cell grafts, and 45% (5/11) were identifiable as human myeloma
chimeras. Pathologic studies showed that most human plasmacytes were
located in the peritoneal cavity but metastatic infiltrates were also found
in other organs in 69% of the SCID-human myeloma chimeras. This chimeric
model should provide a useful tool for characterization of growth
modulation and microenvironmental interactions as well as a means of
testing new therapeutic approaches to multiple myeloma.
Volume 80,
Issue 11,
pp. 2843-2850,
12/01/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S.-Y. Huang, H.-F. Tien, F.-H. Su, and S.-M. Hsu
Nonirradiated NOD/SCID-Human Chimeric Animal Model for Primary Human Multiple Myeloma: A Potential in Vivo Culture System
Am. J. Pathol.,
February 1, 2004;
164(2):
747 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Barton, J. Cullison, J. Jackson, and T. Murphy
A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice
Experimental Biology and Medicine,
February 1, 2000;
223(2):
190 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. M. Pilarski, G. Hipperson, K. Seeberger, E. Pruski, R. W. Coupland, and A. R. Belch
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice
Blood,
February 1, 2000;
95(3):
1056 - 1065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, B. Barlogie, and J. Epstein
Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
Blood,
October 15, 1998;
92(8):
2908 - 2913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J.-F. Rossi, J. Brochier, and B. Klein
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4727 - 4737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsunenari, Y. Koishihara, A. Nakamura, M. Moriya, H. Ohkawa, H. Goto, C. Shimazaki, M. Nakagawa, Y. Ohsugi, T. Kishimoto, et al.
New Xenograft Model of Multiple Myeloma and Efficacy of a Humanized Antibody Against Human Interleukin-6 Receptor
Blood,
September 15, 1997;
90(6):
2437 - 2444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, B. P. Chen, S. Chen, G. S. Pinkus, R. T. Bronson, D. A. Dedera, Y. Hoshi, G. Teoh, A. Ogata, S. P. Treon, et al.
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Blood,
July 15, 1997;
90(2):
754 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
